Search results
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 5 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 5 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 day agoIn the first quarter, Wainua royalty revenues were $1 million. Wainua generated sales of $5 million...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 6 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Democrats ramp up patent fight with drug industry in bid to lower prices
Washington Post· 11 hours agoDemocrats have hit on a new tactic in their long battle with drug companies: challenge patents that...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 3 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 2 days agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 4 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...